FIELD: medicine.
SUBSTANCE: claimed group of inventions relates to medicine, namely to therapy and hematology, and concerns application of stabilisers of HIF-alpha for intensification of erythropoeisis. For this purpose introduced is inhibitor of HIF-prolylhydroxilase, which represents structural mimetic of 2-oxoglutarate, in efficient quantity.
EFFECT: invention ensures treatment and prevention of nemia of different genesis, including, refractive to exogenous introduction of erythropoietin (EPO), due to suppression of anti-inflammatory cytokines, inhibiting EPO synthesis in organism, as well as increase of expression of gene, coding proteins, taking part in synthesis of hemoglobin in vivo.
78 cl, 27 dwg, 5 tbl, 21 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR INCREASING STABILISATION OF HYPOXYA INDUCED FACTOR-1 ALPHA | 2010 |
|
RU2521251C2 |
| COMPOSITIONS AND METHODS OF TREATING ANAEMIA | 2014 |
|
RU2705206C2 |
| COMPOSITIONS AND METHODS OF TREATING COLITIS | 2010 |
|
RU2518416C2 |
| NEW 6-AMINOMORPHINATE DERIVATIVES, METHOD FOR PREPARING THEM AND USING THEM AS ANALGESICS | 2006 |
|
RU2485124C2 |
| N1-(4-(5-(CYCLOPROPYLMETHYL)-1-METHYL-1H-PYRAZOLE-4-YL)PYRIDINE-2-YL)CYCLOHEXANE-1,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF CK1 AND/OR IRAK1 FOR THE TREATMENT OF CANCER | 2018 |
|
RU2761457C2 |
| NOVEL NRP-B AGONISTS | 2010 |
|
RU2557290C2 |
| TREATING CONDITIONS ASSOCIATED WITH HYPERINSULINEMIA | 2015 |
|
RU2722179C2 |
| NEW NPR-B AGONISTS | 2010 |
|
RU2636738C2 |
| PROLYL HYDROXYLASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2429226C9 |
| METHOD FOR EARLY DIAGNOSIS OF PROSTATE TUMORS | 2021 |
|
RU2756643C1 |
